These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34246575)

  • 21. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
    Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
    BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
    Rawal S; Osae SP; Cobran EK; Albert A; Young HN
    Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
    Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
    Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public health detailing to increase naloxone access in NYC pharmacies.
    Foster CL; Tuazon E; Winkelstein E; Kunins HV; Kattan JA
    J Am Pharm Assoc (2003); 2023; 63(3):885-892. PubMed ID: 36997471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Piloting an opioid callback program in community pharmacies.
    Hernandez SE; Gilson AM; Gassman M; Ford JH
    J Am Pharm Assoc (2003); 2023; 63(6):1796-1802. PubMed ID: 37574197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
    Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
    J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of naloxone access and primary medication nonadherence in a community pharmacy setting.
    Connolly E; McCall KL; Couture S; Felton M; Piper BJ; Bratberg JP; Tu C
    J Am Pharm Assoc (2003); 2022; 62(1):49-54. PubMed ID: 34736865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
    Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
    J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacist's role in overdose: Using mapping technologies to analyze naloxone and pharmacy distribution.
    Burrell A; Ethun L; Fawcett JA; Rickard-Aasen S; Williams K; Kearney SM; Pringle JL
    J Am Pharm Assoc (2003); 2017; 57(2S):S73-S77.e1. PubMed ID: 28109629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
    Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
    J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
    Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
    J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
    Xu J; Mukherjee S
    Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
    Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
    Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
    Hill LG; Loera LJ; Evoy KE; Renfro ML; Torrez SB; Zagorski CM; Perez JC; Jones SM; Reveles KR
    Addiction; 2021 Jun; 116(6):1505-1511. PubMed ID: 33140519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal.
    Nielsen S; Menon N; Larney S; Farrell M; Degenhardt L
    Addiction; 2016 Dec; 111(12):2177-2186. PubMed ID: 27367125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.